Thromboxane production in diabetes mellitus

Lorenzo Altomonte, Angelo Zoli, Alessandra Mangia, Giovanni Ghirlanda, Raffaele Manna, Aldo Bertoli, Aldo Virgilio Greco

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A correlation between increased platelet adhesiveness and aggregation and the development of angiopathy in diabetes mellitus can be made. Thromboxane produced by platelets represents a potent platelet aggregation factor. We studied the platelet TXB2 production during blood coagulation in carefully selected patients with type II diabetes mellitus in good metabolic control and the results were correlated with the presence or absence of microangiopathy, fasting blood glucose levels, type of therapy, age, duration of diabetes and the most important hematochemical parameters. No statistically significant differences were found between serum TXB2 concentrations in diabetic patients and control subjects, in diabetics with or without microangiopathy and in diabetics on insulin therapy or on oral hypoglycemic agents. We did not observe any correlation between TXB2 production and age, duration of diabetes, sex, basal blood glucose levels, total and HDL-cholesterol, triglycerides, blood creatinine and blood electrolytes. The thromboxane production may be a not important factor for determining the increased platelet aggregation which is at the origin of the angiopathy in diabetes mellitus.

Original languageEnglish
Pages (from-to)539-542
Number of pages4
JournalLa Ricerca in Clinica e in Laboratorio
Volume16
Issue number4
DOIs
Publication statusPublished - Oct 1986

Fingerprint

Thromboxanes
Medical problems
Platelets
Platelet Aggregation
Diabetes Mellitus
Blood Glucose
Blood Platelets
Platelet Adhesiveness
Blood
Diabetic Angiopathies
Blood Coagulation
Hypoglycemic Agents
Agglomeration
Type 2 Diabetes Mellitus
HDL Cholesterol
Electrolytes
Fasting
Creatinine
Triglycerides
Insulin

Keywords

  • Diabetes mellitus
  • Microangiopathy
  • Platelets
  • Thromboxane

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Altomonte, L., Zoli, A., Mangia, A., Ghirlanda, G., Manna, R., Bertoli, A., & Greco, A. V. (1986). Thromboxane production in diabetes mellitus. La Ricerca in Clinica e in Laboratorio, 16(4), 539-542. https://doi.org/10.1007/BF02886836

Thromboxane production in diabetes mellitus. / Altomonte, Lorenzo; Zoli, Angelo; Mangia, Alessandra; Ghirlanda, Giovanni; Manna, Raffaele; Bertoli, Aldo; Greco, Aldo Virgilio.

In: La Ricerca in Clinica e in Laboratorio, Vol. 16, No. 4, 10.1986, p. 539-542.

Research output: Contribution to journalArticle

Altomonte, L, Zoli, A, Mangia, A, Ghirlanda, G, Manna, R, Bertoli, A & Greco, AV 1986, 'Thromboxane production in diabetes mellitus', La Ricerca in Clinica e in Laboratorio, vol. 16, no. 4, pp. 539-542. https://doi.org/10.1007/BF02886836
Altomonte L, Zoli A, Mangia A, Ghirlanda G, Manna R, Bertoli A et al. Thromboxane production in diabetes mellitus. La Ricerca in Clinica e in Laboratorio. 1986 Oct;16(4):539-542. https://doi.org/10.1007/BF02886836
Altomonte, Lorenzo ; Zoli, Angelo ; Mangia, Alessandra ; Ghirlanda, Giovanni ; Manna, Raffaele ; Bertoli, Aldo ; Greco, Aldo Virgilio. / Thromboxane production in diabetes mellitus. In: La Ricerca in Clinica e in Laboratorio. 1986 ; Vol. 16, No. 4. pp. 539-542.
@article{176237aeb8b443a4a9fddbe6b830c1e8,
title = "Thromboxane production in diabetes mellitus",
abstract = "A correlation between increased platelet adhesiveness and aggregation and the development of angiopathy in diabetes mellitus can be made. Thromboxane produced by platelets represents a potent platelet aggregation factor. We studied the platelet TXB2 production during blood coagulation in carefully selected patients with type II diabetes mellitus in good metabolic control and the results were correlated with the presence or absence of microangiopathy, fasting blood glucose levels, type of therapy, age, duration of diabetes and the most important hematochemical parameters. No statistically significant differences were found between serum TXB2 concentrations in diabetic patients and control subjects, in diabetics with or without microangiopathy and in diabetics on insulin therapy or on oral hypoglycemic agents. We did not observe any correlation between TXB2 production and age, duration of diabetes, sex, basal blood glucose levels, total and HDL-cholesterol, triglycerides, blood creatinine and blood electrolytes. The thromboxane production may be a not important factor for determining the increased platelet aggregation which is at the origin of the angiopathy in diabetes mellitus.",
keywords = "Diabetes mellitus, Microangiopathy, Platelets, Thromboxane",
author = "Lorenzo Altomonte and Angelo Zoli and Alessandra Mangia and Giovanni Ghirlanda and Raffaele Manna and Aldo Bertoli and Greco, {Aldo Virgilio}",
year = "1986",
month = "10",
doi = "10.1007/BF02886836",
language = "English",
volume = "16",
pages = "539--542",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Thromboxane production in diabetes mellitus

AU - Altomonte, Lorenzo

AU - Zoli, Angelo

AU - Mangia, Alessandra

AU - Ghirlanda, Giovanni

AU - Manna, Raffaele

AU - Bertoli, Aldo

AU - Greco, Aldo Virgilio

PY - 1986/10

Y1 - 1986/10

N2 - A correlation between increased platelet adhesiveness and aggregation and the development of angiopathy in diabetes mellitus can be made. Thromboxane produced by platelets represents a potent platelet aggregation factor. We studied the platelet TXB2 production during blood coagulation in carefully selected patients with type II diabetes mellitus in good metabolic control and the results were correlated with the presence or absence of microangiopathy, fasting blood glucose levels, type of therapy, age, duration of diabetes and the most important hematochemical parameters. No statistically significant differences were found between serum TXB2 concentrations in diabetic patients and control subjects, in diabetics with or without microangiopathy and in diabetics on insulin therapy or on oral hypoglycemic agents. We did not observe any correlation between TXB2 production and age, duration of diabetes, sex, basal blood glucose levels, total and HDL-cholesterol, triglycerides, blood creatinine and blood electrolytes. The thromboxane production may be a not important factor for determining the increased platelet aggregation which is at the origin of the angiopathy in diabetes mellitus.

AB - A correlation between increased platelet adhesiveness and aggregation and the development of angiopathy in diabetes mellitus can be made. Thromboxane produced by platelets represents a potent platelet aggregation factor. We studied the platelet TXB2 production during blood coagulation in carefully selected patients with type II diabetes mellitus in good metabolic control and the results were correlated with the presence or absence of microangiopathy, fasting blood glucose levels, type of therapy, age, duration of diabetes and the most important hematochemical parameters. No statistically significant differences were found between serum TXB2 concentrations in diabetic patients and control subjects, in diabetics with or without microangiopathy and in diabetics on insulin therapy or on oral hypoglycemic agents. We did not observe any correlation between TXB2 production and age, duration of diabetes, sex, basal blood glucose levels, total and HDL-cholesterol, triglycerides, blood creatinine and blood electrolytes. The thromboxane production may be a not important factor for determining the increased platelet aggregation which is at the origin of the angiopathy in diabetes mellitus.

KW - Diabetes mellitus

KW - Microangiopathy

KW - Platelets

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=0022789130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022789130&partnerID=8YFLogxK

U2 - 10.1007/BF02886836

DO - 10.1007/BF02886836

M3 - Article

C2 - 3576051

AN - SCOPUS:0022789130

VL - 16

SP - 539

EP - 542

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 4

ER -